Clinical Trials Logo

Clinical Trial Summary

Histiocytic disorders are rare diseases that are characterized by tissue infiltration of histiocytes (dendritic cells) and other inflammatory white blood cells.68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and it might be a pan-tumor PET agent.Recent discoveries have shown that inflammation and fibrosis secondary to mutated histiocytes, rather than a proliferative cell mechanism, result in manifestation of the disease.Thus, the investigators aim to carry out this prospective study to investigate the role of 68Ga-FAPI PET/CT in the diagnosis, therapy response assessment and follow-up of histiocytosis.


Clinical Trial Description

Histiocytic disorders are rare diseases that are characterized by tissue infiltration of histiocytes (dendritic cells) and other inflammatory white blood cells. The archaic term "histiocyte" refers to large white blood cells resident in tissues and includes Langerhans cells, monocytes/macrophages, and dermal/interstitial dendritic cells. The Histiocytic Society classification divides histiocytic disorders into five categories, based on clinical, histologic, immunophenotypic, and molecular features. They are langerhans (L) group, cutaneous and mucocutaneous (C) group, Rosai-Dorfman disease (R) group, malignant histiocytosis (M) group and hemophagocytic lymphohistiocytosis (H) group. Langerhans cell histiocytosis is the most common histiocytic disorder. Less common types include Erdheim-Chester disease, Rosai-Dorfman disease, adult and juvenile xanthogranuloma. Diagnosis, which relies on a multidisciplinary approach, is challenging and often delayed because clinical findings are nonspecific and may mimic malignant processes at radiologic evaluation. Compared with conventional imaging, PET/CT allows detection of the increased metabolic activity in histiocytes and provides a comprehensive whole-body evaluation of their potential involvement with multiple organ systems and allows monitoring of therapeutic response. However, one drawback is that the uptake of FDG is nonspecific because histiocytic lesions may mimic neoplastic processes at PET/CT. And the physiological FDG metabolism in brain, liver and gastrointestinal tract, et al. hampers the detection rate of lesions located in these organs.68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and it might be a pan-tumor PET agent. Although the pathogenesis of histiocytosis may be attributable to mutations in the oncogenic driver, recent discoveries have shown that inflammation and fibrosis secondary to mutated histiocytes, rather than a proliferative cell mechanism, result in manifestation of the disease. Considering 68Ga-FAPI revealing cancer-associated fibroblasts, the investigators aim to carry out this prospective study to investigate the role of 68Ga-FAPI PET/CT in the diagnosis, therapy response assessment and follow-up of histiocytosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05803629
Study type Interventional
Source Peking Union Medical College Hospital
Contact Yaping Luo, MD
Phone 86-10-69155513
Email luoyaping@live.com
Status Not yet recruiting
Phase N/A
Start date May 1, 2023
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Recruiting NCT05915208 - Histiocytic Disorder Follow-up Study
Recruiting NCT04437381 - Molecular Targets for the Treatment of Histiocytosis
Terminated NCT01050439 - Unrelated Donor Transplant for Malignant and Non-Malignant Disorders Phase 2
Active, not recruiting NCT00145626 - HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Phase 2
Recruiting NCT04665674 - Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
Terminated NCT02012231 - Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Phase 1
Completed NCT01225718 - Ceftriaxone in Non-neutropenic Fever N/A
Active, not recruiting NCT03127709 - A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis
Recruiting NCT05786924 - A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Phase 1
Recruiting NCT04943224 - Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients Phase 2
Recruiting NCT04943198 - Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis Phase 2
Recruiting NCT04943211 - Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging Phase 3